

SYNCHRONY 2020 ONLINE

November 1, 8, 15, 22 December 6, 12, 13

International Symposium on Translational Research in Autism From Bench to BioPharma

Synchrony connects cutting-edge autism researchers with practitioners, industry with investors, and involves individuals with autism and their families to help translate research efforts into FDA-approved, evidence-based treatments for autism and its co-morbidities.

Supported by



2020 Participants



November Agenda

Animal Models in ASD Nov 1 | 9 am-2 pm PST

This session presents cutting-edge research into how mouse models are being used to help understand ASD in humans. Animal models can provide insights into effects of gene mutations, and non-behavioral features of ASD, such as the role of the immune system, metabolic system, and gastrointestinal tract including possible contributions by the gut microbiome. Knowledge from these studies may not only help inform human research, but may also prove invaluable in testing therapeutics.

Session Chair: Sarkis Mazmanian, PhD

Speakers:

Laetitia Davidovic, PhD	CNRS, France
Jun Huh, PhD	Harvard
Edward Quadros, PhD	SUNY
Daniel Geschwind, MD	UCLA
Sarkis Mazmanian, PhD	Caltech
Mauro Costa-Mattioli, PhD	BCM
Joseph D. Buxbaum, PhD	Mount Sinai
Elisa Hill-Yardin, PhD	RMIT, Australia

Organoid Research, Immunology and Neuro-metabolism Nov 8 | 9-11 am, 12-2 pm, 3-5 pm PST

The morning session highlights basic science research including organoid development and immunological research related to testing and treatment in ASD.

Speakers:

Organoids

Paul Ashwood, PhD	UC Davis
Tanja Michel, PhD / Mirolyuba Ilieva, PhD	SDU/ Odense University Hospital

Immunology

Jonathan Kipnis, PhD	WU
Andrew McKeon, MD	Mayo Clinic
Lisa Boulanger, PhD	Princeton
Harumi Jyonouchi, MD	St. Peters' Hospital
Emanuela Balestrieri, PhD	University of Rome
Marion Leboyer, MD, PhD	University of Paris

The afternoon session focusses on neuro-metabolic studies in ASD, including a focus on anti-folate antibodies and treatments, mitochondrial dysfunction and chemical signalling in the nervous system.

Speakers:

Neuro-metabolic Studies

Randy Blakely, PhD	FAU, NIMH
Vincent Ramaekers, MD	Univ of Liege, Belgium
Edward Quadros, PhD	SUNY
Robert Naviaux, MD, PhD	UCSD
Richard Boles, MD	Private Practice
Richard Frye, MD, PhD	Phoenix Childrens' Hospital

Microbiome/GI research Nov 15 | 1-4 pm PST

Several research studies link gastrointestinal comorbidities to a variety of debilitating symptoms in individuals with ASD at all ages. Improvements in GI symptoms are linked to improvements in behavior & quality of life. This session highlights the latest work in microbiome studies, therapeutics in FDA trials, updates on a longitudinal GI treatment study, & biopsy studies to characterize inflammatory conditions in individuals with ASD.

Session Chairs: Jim Adams, PhD & Rosa Krajmalnik-Brown, PhD

Speakers:

Microbiome/GI

Jim Adams, PhD & Rosa Krajmalnik-Brown, PhD	ASU
Frederico Balzola, MD	Torino Piedmont, Italy
Arthur Krigsman, MD	Private Practice
Steve Walker, PhD	Wake Forest Univ.

Microbiota Therapies

Jim Adams, PhD & Rosa Krajmalnik-Brown, PhD	ASU
Sabine Hazan Steinberg, MD	Private Practice
Sonia Michail, MD	CHLA

Panel Discussion: Repurposed drugs as ASD

Therapeutics
Dr Rossignol, MD, Dr Jyonouchi, MD, Dr Krigsman, MD, Dr Adams, PhD & Dr Yeh, MD

Physicians Present Treatments on the Horizon in ASD Nov 22 | 10 am-12 pm, 1-4 pm PST

This session presents researchers and physicians with the latest on treatments and solutions geared towards educating physicians, parents and caregivers. Topics range from CBD studies, mitochondrial dysfunction, GI symptoms, to biophotonic devices.

Speakers:

Treatments on the Horizon

Antonio Hardan, MD	Stanford
Joanne Kurtzberg, MD	Duke Center for Autism
Adi Aran, MD	Shaare Tzedek Medical Center, Israel
Yezeckel Ben Ari, PhD	Inmed, Neurichlore
Peter Lloyd-Thomas	Epiphany ASD
Arthur Krigsman, MD	Private Practice

Device Panel

Anita SaltMarche, MHSc	Private Practice
Michael Hamblin, PhD	Harvard
Margaret Naeser, PhD	Boston University
Paolo Cassano, MD, PhD	Harvard, Mass General

December Agenda

Clinical Trials for Therapeutics in ASD Dec 6 | 9 am- 12 pm, 1-5pm PST

This session brings together industry and academia with a focus on clinical trials.

Academic Sessions: The morning session highlights assessments in ASD clinical trials in the time of COVID

Session Chair: Stewart Campbell, PhD

Speakers:

Bob Hendren, DO	UCSF
Pam Ventola, PhD	Yale
Sophy Kim, PhD	Cornell
Whitney Ence, PhD	UCSF
Ann Neumeyer, PhD	MGH, Harvard
Lisa Nowinski, PhD	MGH, Harvard

Industry Presentations: Industry experts from startups and large pharma will discuss ongoing clinical trials and therapeutics on the path to FDA approval.

Speakers:

Manuela Ingallinesi	Servier
Chris Chatham, PhD	Roche
Gahan Pandina, PhD	Johnson and Johnson
Joan Fallon, MSc	Curemark
Kevin Sanders, MD	Roche
Jim Adams, PhD & Rosa Krajmalnik-Brown, PhD	ASU

Novel Therapeutics Dec 12 | 10 am-12 pm, 1-3 pm PST

This session highlights novel therapeutics from leaders in academia and industry. Leading companies present products in the pipeline for ASD.

Keynote: Stuart Lipton, MD, PhD

Speakers:

Robert Naviaux, MD, PhD	UCSD
Joseph Palumbo, MD	Zynerba Pharma
Stuart Lipton, MD, PhD	Scripps/UCSD
Paul Song, MD	NK Max America
John Rodakis	N of One
Mark Smith	Finch Therapeutics
Nebojsa Janjic, PhD	Crestone Pharma
Suzanne Goh, MD	Cortica

Biomarker Research and Coordinated Clinical Care Dec 13 | 10 am- 12 pm, 1-3 pm PST

This session brings together academic and industry efforts at establishing biomarkers to help diagnose sub-types of medical comorbidities in autism and to measure response to therapeutics and clinical trials.

The biomarker track presents leaders and innovators involved in discovering biomarkers to help identify and track conditions in people with ASD.

Session Chair: John Slattery

Speakers:

John Slattery	Bio Rosa
Chris Chatham, PhD	Roche
Mark Smith	Finch Therapeutics
Alessio Fasano, MD	Mass General
Judy Van de Water, PhD	UC Davis
Matt Anderson, MD, PhD	Harvard

Panel Discussion: Clinical Validation and Biomarkers- what do they do for diagnostics and treatment tracking with Richard Frye, MD, PhD

Participating Industry Leaders

